Sandoz announces acquisition of Pfizer's biosimilar infliximab in EEA
Sandoz announced it has acquired from Pfizer the rights for the development and commercialization of PF-06438179 (biosimilar infliximab) in the 28 countries that form the European Economic Area. Infliximab is a tumor necrosis factor alpha inhibitor used to treat a range of autoimmune diseases. February 11, 2016